E-cM-Topi / Jiangsu Hengrui Pharma - LARVOL DELTA

E-cM-Topi, a potent EGFR-cMET bispecific antibody drug conjugate, with superior anti-tumor effect in non-small-cell lung cancer (NSCLC) (AACR 2025) - "In summary, by fine-tuning the EGFR-cMET bispecific antibody affinity and incorporating a superior bystander effect of payload, E-cM-Topi represents a best-in-class potential. It holds promise as an effective treatment option for EGFR-TKI resistant NSCLC patients."

Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • MET • TOP1